Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ICCM Stock Forecast 2025-2026
$0.97
Current Price
$56.98M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ICCM Price Targets
+263.2%
To High Target of $3.53
+208.6%
To Median Target of $3.00
+157.2%
To Low Target of $2.50
ICCM Price Momentum
-6.7%
1 Week Change
-6.7%
1 Month Change
+18.3%
1 Year Change
-11.8%
Year-to-Date Change
-41.4%
From 52W High of $1.66
+102.5%
From 52W Low of $0.48
📊 TOP ANALYST CALLS
Did ICCM Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if IceCure is one of their latest high-conviction picks.
Latest ICCM Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, ICCM has a bullish consensus with a median price target of $3.00 (ranging from $2.50 to $3.53). Currently trading at $0.97, the median forecast implies a 208.6% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Yi Chen at HC Wainwright & Co., suggesting a 157.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ICCM Analyst Ratings
3
Buy
0
Hold
0
Sell
ICCM Price Target Range
Low
$2.50
Average
$3.00
High
$3.53
Current: $0.97
Latest ICCM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ICCM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 29, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $2.50 |
| Mar 28, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $2.50 |
| Nov 27, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $2.50 |
| Nov 8, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $2.50 |
| Sep 12, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $2.50 |
| Aug 21, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $2.50 |
| Jul 2, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
| Jun 5, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
| May 29, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
| Apr 16, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
| Apr 4, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
| Mar 20, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
| Mar 20, 2024 | Alliance Global Partners | Ben Haynor | Buy | Maintains | $2.90 |
| Mar 5, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
| Nov 29, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
| Sep 6, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
| Aug 15, 2023 | Alliance Global Partners | Ben Haynor | Buy | Maintains | $4.00 |
| Aug 15, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
| Jul 25, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
| Jun 1, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
IceCure Medical Ltd. (ICCM) Competitors
The following stocks are similar to IceCure based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
IceCure Medical Ltd. (ICCM) Financial Data
IceCure Medical Ltd. has a market capitalization of $56.98M with a P/E ratio of 0.0x. The company generates $3.27M in trailing twelve-month revenue with a 44.1% profit margin.
Revenue growth is -2.4% quarter-over-quarter, while maintaining an operating margin of -504.4% and return on equity of -173.5%.
Valuation Metrics
Market Cap
$56.98M
Enterprise Value
$51.32M
P/E Ratio
0.0x
PEG Ratio
-3.9x
Price/Sales
17.4x
Growth & Margins
Revenue Growth (YoY)
-2.4%
Gross Margin
+30.1%
Operating Margin
-504.4%
Net Margin
+44.1%
EPS Growth
-2.4%
Financial Health
Cash/Price Ratio
+10.6%
Current Ratio
1.9x
Debt/Equity
6.3x
ROE
-173.5%
ROA
-72.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
IceCure Medical Ltd. (ICCM) Business Model
About IceCure Medical Ltd.
What They Do
Innovative cryoablation technology for cancer treatment.
Business Model
IceCure Medical Ltd. generates revenue by developing and selling advanced cryoablation devices that provide minimally invasive treatment for various types of cancer. The company focuses on offering solutions that enhance patient recovery times and reduce surgical risks, appealing to oncologists and healthcare facilities seeking effective treatment alternatives.
Additional Information
Based in Israel, IceCure is a key player in the medical technology market, continuously innovating to improve the safety and efficacy of its products. The company collaborates with medical professionals to expand its global reach and impact, positioning itself as a leader in cryogenic solutions within the oncology sector.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
64
CEO
Mr. Eyal Shamir
Country
Israel
IPO Year
2011
Website
www.icecure-medical.comIceCure Medical Ltd. (ICCM) Latest News & Analysis
Latest News
Quick Summary
IceCure Medical (NASDAQ: ICCM) holds 20+ U.S. patents and expects increased market traction following an FDA marketing authorization decision for its cryoablation technology in early-stage breast cancer.
Why It Matters
IceCure's patent allowance strengthens its intellectual property position and could boost competitive advantage, while FDA authorization may drive market growth and investor interest in its innovative technology.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
IceCure Medical Ltd (NASDAQ:ICCM) will hold its Q1 2025 Earnings Conference Call on May 28, 2025, at 10:00 AM ET, featuring CEO Eyal Shamir and CFO Ronen Tsimerman.
Why It Matters
The upcoming earnings call for IceCure Medical may provide insights into the company's financial health and strategic direction, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
IceCure Medical Ltd. has submitted a post-market study plan to the FDA for ProSense® targeting women 70+ with low-risk breast cancer and will hold a conference call today at 10 AM ET.
Why It Matters
The FDA's review of IceCure's ProSense® could impact market access and sales. Rising interest in North America suggests potential for revenue growth, influencing investor sentiment and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
IceCure Medical Ltd. (Nasdaq: ICCM) will release its financial and operational results for Q1 2025 on May 28, 2025, before the market opens.
Why It Matters
IceCure Medical's upcoming financial results could impact its stock price, reflecting its growth potential and market position in the minimally-invasive cancer treatment sector.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
IceCure Medical's ProSense® study for early-stage breast cancer received strong interest from surgeons. The ICE3 study was highlighted at the ASBrS 2025 meeting, indicating positive industry engagement.
Why It Matters
Strong interest from surgeons in IceCure's study and positive reception of cryoablation may enhance market position and investor confidence, potentially boosting stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
IceCure Medical awaits FDA approval for its ProSense® system, a minimally invasive treatment for early-stage breast cancer. A post-market study is planned to gather more data post-authorization.
Why It Matters
Approval of IceCure's ProSense® could disrupt breast cancer treatment, offering a novel, minimally invasive option. Anticipated FDA decision and post-market study may drive stock value and market interest.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ICCM Stock
What is IceCure Medical Ltd.'s (ICCM) stock forecast for 2025?
Based on our analysis of 5 Wall Street analysts, IceCure Medical Ltd. (ICCM) has a median price target of $3.00. The highest price target is $3.53 and the lowest is $2.50.
Is ICCM stock a good investment in 2025?
According to current analyst ratings, ICCM has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.97. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ICCM stock?
Wall Street analysts predict ICCM stock could reach $3.00 in the next 12 months. This represents a 208.6% increase from the current price of $0.97. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is IceCure Medical Ltd.'s business model?
IceCure Medical Ltd. generates revenue by developing and selling advanced cryoablation devices that provide minimally invasive treatment for various types of cancer. The company focuses on offering solutions that enhance patient recovery times and reduce surgical risks, appealing to oncologists and healthcare facilities seeking effective treatment alternatives.
What is the highest forecasted price for ICCM IceCure Medical Ltd.?
The highest price target for ICCM is $3.53 from at , which represents a 263.2% increase from the current price of $0.97.
What is the lowest forecasted price for ICCM IceCure Medical Ltd.?
The lowest price target for ICCM is $2.50 from Yi Chen at HC Wainwright & Co., which represents a 157.2% increase from the current price of $0.97.
What is the overall ICCM consensus from analysts for IceCure Medical Ltd.?
The overall analyst consensus for ICCM is bullish. Out of 5 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $3.00.
How accurate are ICCM stock price projections?
Stock price projections, including those for IceCure Medical Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 16, 2025 11:21 AM UTC